Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Coptisine inhibits RANKL-induced NF-κB phosphorylation in osteoclast precursors and suppresses function through the regulation of RANKL and OPG gene expression in osteoblastic cells.

Lee JW, Iwahashi A, Hasegawa S, Yonezawa T, Jeon WB, Cha BY, Nagai K, Woo JT.

J Nat Med. 2012 Jan;66(1):8-16. doi: 10.1007/s11418-011-0537-7. Epub 2011 Jun 9.

PMID:
21656335
2.

Action of RANKL and OPG for osteoclastogenesis.

Kobayashi Y, Udagawa N, Takahashi N.

Crit Rev Eukaryot Gene Expr. 2009;19(1):61-72. Review.

PMID:
19191757
3.

Receptor activator of nuclear factor-κB ligand and osteoprotegerin: maintaining the balance to prevent bone loss.

Trouvin AP, Goëb V.

Clin Interv Aging. 2010 Nov 19;5:345-54. doi: 10.2147/CIA.S10153. Review.

4.

Regulatory mechanism of osteoclastogenesis by RANKL and Wnt signals.

Takahashi N, Maeda K, Ishihara A, Uehara S, Kobayashi Y.

Front Biosci (Landmark Ed). 2011 Jan 1;16:21-30. Review.

PMID:
21196156
5.

[Control of bone resorption by RANKL-RANK system].

Harada S, Takahashi N.

Clin Calcium. 2011 Aug;21(8):1121-30. doi: CliCa110811211130. Review. Japanese.

PMID:
21814016
6.

Regulators of osteoclast differentiation and cell-cell fusion.

Miyamoto T.

Keio J Med. 2011;60(4):101-5. Review.

7.

Cell-based assay strategy for identification of motif-specific RANK signaling pathway inhibitors.

Chen T, Feng X.

Assay Drug Dev Technol. 2006 Aug;4(4):473-82. Review.

PMID:
16945019
8.

Regulatory mechanisms of RANKL presentation to osteoclast precursors.

Honma M, Ikebuchi Y, Kariya Y, Suzuki H.

Curr Osteoporos Rep. 2014 Mar;12(1):115-20. doi: 10.1007/s11914-014-0189-0. Review.

PMID:
24477414
9.

Receptor activator of nuclear factor-κB ligand (RANKL)/RANK/osteoprotegerin system in bone and other tissues (review).

Liu W, Zhang X.

Mol Med Rep. 2015 May;11(5):3212-8. doi: 10.3892/mmr.2015.3152. Epub 2015 Jan 7. Review.

PMID:
25572286
10.

Mechanism of inhibitory action of eldecalcitol, an active vitamin D analog, on bone resorption in vivo.

Takahashi N.

J Steroid Biochem Mol Biol. 2013 Jul;136:171-4. doi: 10.1016/j.jsbmb.2012.11.010. Epub 2012 Dec 5. Review.

PMID:
23220095
11.

The osteoclast, bone remodelling and treatment of metabolic bone disease.

Boyce BF, Rosenberg E, de Papp AE, Duong LT.

Eur J Clin Invest. 2012 Dec;42(12):1332-41. doi: 10.1111/j.1365-2362.2012.02717.x. Epub 2012 Sep 23. Review.

PMID:
22998735
12.

New insights into osteoclastogenic signaling mechanisms.

Nakashima T, Hayashi M, Takayanagi H.

Trends Endocrinol Metab. 2012 Nov;23(11):582-90. doi: 10.1016/j.tem.2012.05.005. Epub 2012 Jun 15. Review.

PMID:
22705116
13.

The role of cytokines in inflammatory bone loss.

Souza PP, Lerner UH.

Immunol Invest. 2013;42(7):555-622. doi: 10.3109/08820139.2013.822766. Review.

PMID:
24004059
14.

New regulation mechanisms of osteoclast differentiation.

Nakashima T, Takayanagi H.

Ann N Y Acad Sci. 2011 Dec;1240:E13-8. doi: 10.1111/j.1749-6632.2011.06373.x. Review.

PMID:
22360322
15.

RANKL/RANK as key factors for osteoclast development and bone loss in arthropathies.

Leibbrandt A, Penninger JM.

Adv Exp Med Biol. 2009;649:100-13. Review.

PMID:
19731623
16.

Functions of RANKL/RANK/OPG in bone modeling and remodeling.

Boyce BF, Xing L.

Arch Biochem Biophys. 2008 May 15;473(2):139-46. doi: 10.1016/j.abb.2008.03.018. Epub 2008 Mar 25. Review.

17.

RANKL inhibition for the management of patients with benign metabolic bone disorders.

Anastasilakis AD, Toulis KA, Polyzos SA, Terpos E.

Expert Opin Investig Drugs. 2009 Aug;18(8):1085-102. doi: 10.1517/13543780903048929. Review.

PMID:
19558335
18.

Roles of Wnt signals in bone resorption during physiological and pathological states.

Maeda K, Takahashi N, Kobayashi Y.

J Mol Med (Berl). 2013 Jan;91(1):15-23. doi: 10.1007/s00109-012-0974-0. Epub 2012 Oct 31. Review.

PMID:
23111637
19.

[Research on regulation mechanism of osteoclast differentiation].

Song CY, Peng B, Shen JY, Jin HT, Xiao LW, Tong PJ.

Zhongguo Gu Shang. 2015 Jun;28(6):580-4. Review. Chinese.

PMID:
26255490
20.

[The role of RANK/RANKL and OPG in multiple myeloma].

Zdzisińska B, Kandefer-Szerszeń M.

Postepy Hig Med Dosw (Online). 2006;60:471-82. Review. Polish.

Supplemental Content

Support Center